Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - oxycodone hydrochloride, quantity: 10 mg - tablet, modified release - excipient ingredients: titanium dioxide; stearic acid; behenoyl polyoxyglycerides; copovidone; maize starch; lactose monohydrate; magnesium stearate; hydrogenated castor oil; hypromellose; colloidal anhydrous silica; microcrystalline cellulose; medium chain triglycerides - oxycodone sandoz modified release tablet is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long term treatment. oxycodone sandoz modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. oxycodone sandoz modified release tablet is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - oxycodone hydrochloride, quantity: 80 mg - tablet, modified release - excipient ingredients: copovidone; colloidal anhydrous silica; lactose monohydrate; behenoyl polyoxyglycerides; titanium dioxide; hydrogenated castor oil; stearic acid; magnesium stearate; medium chain triglycerides; maize starch; microcrystalline cellulose; hypromellose; iron oxide black; colour - oxycodone sandoz modified release tablet is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long term treatment. oxycodone sandoz modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. oxycodone sandoz modified release tablet is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - pantoprazole sodium sesquihydrate, quantity: 45.12 mg (equivalent: pantoprazole, qty 40 mg) - injection, powder for - excipient ingredients: nitrogen - pantoprazole sandoz is indicated for short-term use where oral therapy is not appropriate for the following conditions: 1. symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion, e.g. duodenal ulcer, gastric ulcer, reflux oesophagitis, gastrointestinal lesions refractory to h2 blockers, zollinger-ellison syndrome. 2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. note: patients who gastric or duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with anti-microbial agents in addition to anti-secretory medicines, whether on first presentation or recurrence.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - omeprazole sodium, quantity: 42.56 mg (equivalent: omeprazole, qty 40 mg) - injection, powder for - excipient ingredients: nitrogen; sodium hydroxide; disodium edetate - short-term use when omeprazole cannot be administered orally for, or during, the following conditions. treatment of duodenal ulcer, gastric ulcer and ulcerative oesophagitis. treatment of zollinger-ellison syndrome. long-term prevention of relapse in healed severe reflux oesophagitis (grades 3 and 4), and gastric and duodenal peptic ulceration in patients proven to be helicobacter pylori negative whose ulceration is not associated with ingestion of nsaids, when oral therapy is not possible. omeprazole sandoz iv should be replaced with oral therapy as soon as practicable

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - enalapril maleate, quantity: 20 mg - tablet, uncoated - excipient ingredients: maize starch; sodium bicarbonate; lactose monohydrate; iron oxide red; iron oxide yellow; magnesium stearate; purified talc - indications: hypertension. all grades of essential hypertension; renovascular hypertension. congestive heart failure. treatment of all degrees of symptomatic heart failure. in such patients it is recommended that enalapril sandoz be administered together with a diuretic. left ventricular dysfunction. all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35%, irrespective of the presence of severity of obvious symptoms of heart failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - enalapril maleate, quantity: 10 mg - tablet, uncoated - excipient ingredients: maize starch; sodium bicarbonate; lactose monohydrate; iron oxide red; purified talc; magnesium stearate - indications: hypertension. all grades of essential hypertension; renovascular hypertension. congestive heart failure. treatment of all degrees of symptomatic heart failure. in such patients it is recommended that enalapril sandoz be administered together with a diuretic. left ventricular dysfunction. all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35%, irrespective of the presence or severity of obvious symptoms of heart failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - enalapril maleate, quantity: 5 mg - tablet, uncoated - excipient ingredients: maize starch; sodium bicarbonate; lactose monohydrate; hyprolose; purified talc; magnesium stearate - indications: hypertension. all grades of essential hypertension; renovascular hypertension. congestive heart failure. treatment of all degrees of symptomatic heart failure. in such patients it is recommended that enalapril sandoz be administered together with a diuretic. left ventricular dysfunction. all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35%, irrespective of the presence or severity of obvious symptoms of heart failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - simvastatin, quantity: 40 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; citric acid monohydrate; lactose monohydrate; purified talc; ascorbic acid; hypromellose; pregelatinised maize starch; butylated hydroxyanisole; titanium dioxide; iron oxide red; magnesium stearate - adjunct to diet for treatment of hypercholesterolaemia. prior to initiating therapy with simvastatin sandoz, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.,simvastatin sandoz is indicated in patients at high risk of coronary heart disease (chd) (with or without hypercholesterolaemia) including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, hospitalisation due to angina pectoris. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.,simvastatin sandoz is indicated as an adjunct to diet in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heterozygous familial hypercholesterolaemia (hefh). prior to initiating therapy with simvastatin sandoz, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - simvastatin, quantity: 20 mg - tablet, film coated - excipient ingredients: magnesium stearate; iron oxide yellow; titanium dioxide; citric acid monohydrate; purified talc; ascorbic acid; lactose monohydrate; hypromellose; microcrystalline cellulose; pregelatinised maize starch; iron oxide red; butylated hydroxyanisole - adjunct to diet for treatment of hypercholesterolaemia. prior to initiating therapy with simvastatin sandoz, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.,simvastatin sandoz is indicated in patients at high risk of coronary heart disease (chd) (with or without hypercholesterolaemia) including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, hospitalisation due to angina pectoris. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.,simvastatin sandoz is indicated as an adjunct to diet in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heterozygous familial hypercholesterolaemia (hefh). prior to initiating therapy with simvastatin sandoz, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - simvastatin, quantity: 10 mg - tablet, film coated - excipient ingredients: citric acid monohydrate; lactose monohydrate; titanium dioxide; ascorbic acid; hypromellose; purified talc; microcrystalline cellulose; iron oxide yellow; pregelatinised maize starch; iron oxide red; magnesium stearate; butylated hydroxyanisole - adjunct to diet for treatment of hypercholesterolaemia. prior to initiating therapy with simvastatin sandoz, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.,simvastatin sandoz is indicated in patients at high risk of coronary heart disease (chd) (with or without hypercholesterolaemia) including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, hospitalisation due to angina pectoris. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.,simvastatin sandoz is indicated as an adjunct to diet in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heterozygous familial hypercholesterolaemia (hefh). prior to initiating therapy with simvastatin sandoz, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.